Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-25T13:10:04.826Z Has data issue: false hasContentIssue false
  • English
  • Français

Treating negative symptoms of schizophrenia: current approaches and future perspectives

Published online by Cambridge University Press:  05 June 2023

Oliver Howes Open the ORCID record for Oliver Howes [Opens in a new window] ,
Paolo Fusar-Poli  and
Martin Osugo
Oliver Howes*
Affiliation:
Department of Psychosis Studies, King's College London, UK
Paolo Fusar-Poli
Affiliation:
Department of Psychosis Studies, King's College London, UK Department of Brain and Behavioral Health Sciences, University of Pavia, Italy
Martin Osugo
Affiliation:
Department of Psychosis Studies, King's College London, UK
*
Correspondence: Oliver Howes. Email: oliver.howes@kcl.ac.uk
Get access Rights & Permissions [Opens in a new window]

Summary

Negative symptoms are core symptoms of schizophrenia which are common throughout the course of the illness. We outline their functional impact, before reviewing the latest research and guidelines on their assessment and treatment. Finally, we discuss conceptual issues related to measurement of negative symptoms and approaches to address these.

Keywords

Antipsychoticspsychosisanhedoniatrialoutcome
Type
Analysis
Information
The British Journal of Psychiatry , Volume 223 , Special Issue 1: Themed Issue: Negative Symptoms of Schizophrenia , July 2023 , pp. 332 - 335
Check for updates
Copyright
Copyright © The Author(s), 2023. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Galderisi, S, Mucci, A, Buchanan, RW, Arango, C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry 2018; 5: 664–77.CrossRefGoogle ScholarPubMed
Valle, R. Schizophrenia in ICD-11: comparison of ICD-10 and DSM-5. Rev Psiquiatr Salud Ment (Engl Ed) 2020; 13: 95–104.CrossRefGoogle ScholarPubMed
Kirkpatrick, B, Fenton, WS, Carpenter, WT Jr., Marder, SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006; 32: 214–9.CrossRefGoogle ScholarPubMed
Haguiara, B, Koga, G, Diniz, E, Fonseca, L, Higuchi, CH, Kagan, S, et al. What is the best latent structure of negative symptoms in schizophrenia? A systematic review. Schizophr Bull Open 2021; 2(1): sgab013.Google ScholarPubMed
Sauvé, G, Brodeur, MB, Shah, JL, Lepage, M. The prevalence of negative symptoms across the stages of the psychosis continuum. Harv Rev Psychiatry 2019; 27: 15–32.CrossRefGoogle ScholarPubMed
Rabinowitz, J, Werbeloff, N, Caers, I, Mandel, FS, Stauffer, V, Menard, F, et al. Negative symptoms in schizophrenia – the remarkable impact of inclusion definitions in clinical trials and their consequences. Schizophr Res 2013; 150: 334–8.CrossRefGoogle ScholarPubMed
Santesteban-Echarri, O, Paino, M, Rice, S, González-Blanch, C, McGorry, P, Gleeson, J, et al. Predictors of functional recovery in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. Clin Psychol Rev 2017; 58: 59–75.CrossRefGoogle ScholarPubMed
Ventura, J, Hellemann, GS, Thames, AD, Koellner, V, Nuechterlein, KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res 2009; 113: 189–99.CrossRefGoogle ScholarPubMed
Degnan, A, Berry, K, Sweet, D, Abel, K, Crossley, N, Edge, D. Social networks and symptomatic and functional outcomes in schizophrenia: a systematic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol 2018; 53: 873–88.CrossRefGoogle ScholarPubMed
Eack, SM, Newhill, CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull 2007; 33: 1225–37.CrossRefGoogle ScholarPubMed
Fusar-Poli, P, Estradé, A, Stanghellini, G, Venables, J, Onwumere, J, Messas, G, et al. The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics. World Psychiatry 2022; 21: 168–88.CrossRefGoogle ScholarPubMed
Sicras-Mainar, A, Maurino, J, Ruiz-Beato, E, Navarro-Artieda, R. Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia. Neuropsychiatr Dis Treat 2015; 11: 51–7.Google Scholar
Patel, R, Jayatilleke, N, Broadbent, M, Chang, CK, Foskett, N, Gorrell, G, et al. Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method. BMJ Open 2015; 5(9): e007619.CrossRefGoogle Scholar
Weber, S, Scott, JG, Chatterton, ML. Healthcare costs and resource use associated with negative symptoms of schizophrenia: a systematic literature review. Schizophr Res 2022; 241: 251–9.CrossRefGoogle ScholarPubMed
Storch Jakobsen, A, Speyer, H, Nørgaard, HCB, Hjorthøj, C, Krogh, J, Mors, O, et al. Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders – Baseline and two-years findings from the CHANGE trial. Schizophr Res 2018; 199: 96–102.CrossRefGoogle ScholarPubMed
Vancampfort, D, Rosenbaum, S, Probst, M, Soundy, A, Mitchell, AJ, De Hert, M, et al. Promotion of cardiorespiratory fitness in schizophrenia: a clinical overview and meta-analysis. Acta Psychiatri Scand 2015; 132: 131–43.CrossRefGoogle ScholarPubMed
Oliver, D, Reilly, TJ, Baccaredda Boy, O, Petros, N, Davies, C, Borgwardt, S, et al. What causes the onset of psychosis in individuals at clinical high risk? A meta-analysis of risk and protective factors. Schizophr Bull 2020; 46: 110–20.CrossRefGoogle Scholar
Fusar-Poli, P, Correll, CU, Arango, C, Berk, M, Patel, V, Ioannidis, JPA. Preventive psychiatry: a blueprint for improving the mental health of young people. World Psychiatry 2021; 20: 200–21.CrossRefGoogle ScholarPubMed
Howes, OD, Whitehurst, T, Shatalina, E, Townsend, L, Onwordi, EC, Mak, TLA, et al. The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis. World Psychiatry 2021; 20: 75–95.CrossRefGoogle ScholarPubMed
Okada, H, Hirano, D, Taniguchi, T. Impact of negative symptom domains and other clinical characteristics on functional outcomes in patients with schizophrenia. Schizophr Res Treatment 2021; 2021: 8864352.Google ScholarPubMed
Rabinowitz, J, Levine, SZ, Garibaldi, G, Bugarski-Kirola, D, Berardo, CG, Kapur, S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res 2012; 137: 147–50.CrossRefGoogle ScholarPubMed
Kirschner, M, Aleman, A, Kaiser, S. Secondary negative symptoms – a review of mechanisms, assessment and treatment. Schizophr Res 2017; 186: 29–38.CrossRefGoogle ScholarPubMed
Krynicki, CR, Upthegrove, R, Deakin, JFW, Barnes, TRE. The relationship between negative symptoms and depression in schizophrenia: a systematic review. Acta Psychiatr Scand 2018; 137: 380–90.CrossRefGoogle ScholarPubMed
Edwards, CJ, Garety, P, Hardy, A. The relationship between depressive symptoms and negative symptoms in people with non-affective psychosis: a meta-analysis. Psychol Med 2019; 49: 2486–98.CrossRefGoogle ScholarPubMed
Lako, IM, Bruggeman, R, Knegtering, H, Wiersma, D, Schoevers, RA, Slooff, CJ, et al. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J Affect Disord 2012; 140: 38–47.CrossRefGoogle ScholarPubMed
López-Díaz, Á, Lara, I, Lahera, G. Is the prevalence of the deficit syndrome in schizophrenia higher than estimated? Results of a meta-analysis. Psychiatry Investig 2018; 15: 94–8.CrossRefGoogle ScholarPubMed
Ahmed, AO, Strauss, GP, Buchanan, RW, Kirkpatrick, B, Carpenter, WT. Are negative symptoms dimensional or categorical? Detection and validation of deficit schizophrenia with taxometric and latent variable mixture models. Schizophr Bull 2015; 41: 879–91.CrossRefGoogle ScholarPubMed
Galderisi, S, Mucci, A, Dollfus, S, Nordentoft, M, Falkai, P, Kaiser, S, et al. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry 2021; 64(1): e23.CrossRefGoogle ScholarPubMed
Németh, G, Laszlovszky, I, Czobor, P, Szalai, E, Szatmári, B, Harsányi, J, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet 2017; 389: 1103–13.CrossRefGoogle ScholarPubMed
Devoe, DJ, Peterson, A, Addington, J. Negative symptom interventions in youth at risk of psychosis: a systematic review and network meta-analysis. Schizophr Bull 2018; 44: 807–23.CrossRefGoogle ScholarPubMed
Leucht, S, Leucht, C, Huhn, M, Chaimani, A, Mavridis, D, Helfer, B, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 2017; 174: 927–42.CrossRefGoogle ScholarPubMed
Huhn, M, Nikolakopoulou, A, Schneider-Thoma, J, Krause, M, Samara, M, Peter, N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394: 939–51.CrossRefGoogle ScholarPubMed
Krause, M, Zhu, Y, Huhn, M, Schneider-Thoma, J, Bighelli, I, Nikolakopoulou, A, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2018; 268: 625–39.CrossRefGoogle ScholarPubMed
Correll, CU, Rubio, JM, Inczedy-Farkas, G, Birnbaum, ML, Kane, JM, Leucht, S. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 2017; 74: 675–84.CrossRefGoogle ScholarPubMed
Lobo, MC, Whitehurst, TS, Kaar, SJ, Howes, OD. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev 2022; 132: 324–61.CrossRefGoogle ScholarPubMed
Correll, CU, Abi-Dargham, A, Howes, O. Emerging treatments in schizophrenia. J Clin Psychiatry 2022; 83(1): SU21204IP1.CrossRefGoogle ScholarPubMed
Bugarski-Kirola, D, Arango, C, Fava, M, Nasrallah, H, Liu, IY, Abbs, B, et al. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry 2022; 9: 46–58.CrossRefGoogle ScholarPubMed
Davidson, M, Saoud, J, Staner, C, Noel, N, Luthringer, E, Werner, S, et al. Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry 2017; 174: 1195–202.CrossRefGoogle ScholarPubMed
Davidson, M, Saoud, J, Staner, C, Noel, N, Werner, S, Luthringer, E, et al. Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia. Schizophr Bull 2022; 48: 609–19.CrossRefGoogle ScholarPubMed
Czobor, P, Sebe, B, Acsai, K, Barabássy, Á, Laszlovszky, I, Németh, G, et al. What is the minimum clinically important change in negative symptoms of schizophrenia? PANSS based post-hoc analyses of a phase III clinical trial. Front Psychiatry 2022; 13: 816339.CrossRefGoogle ScholarPubMed
Fusar-Poli, P, Papanastasiou, E, Stahl, D, Rocchetti, M, Carpenter, W, Shergill, S, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 2015; 41: 892–9.CrossRefGoogle ScholarPubMed
Hieronymus, F, Jauhar, S, Østergaard, SD, Young, AH. One (effect) size does not fit at all: interpreting clinical significance and effect sizes in depression treatment trials. J Psychopharmacol 2020; 34: 1074–8.CrossRefGoogle Scholar
Salazar de Pablo, G, Besana, F, Arienti, V, Catalan, A, Vaquerizo-Serrano, J, Cabras, A, et al. Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis. EClinicalMedicine 2021; 36: 100909.CrossRefGoogle ScholarPubMed
Salazar de Pablo, G, Soardo, L, Cabras, A, Pereira, J, Kaur, S, Besana, F, et al. Clinical outcomes in individuals at clinical high risk of psychosis who do not transition to psychosis: a meta-analysis. Epidemiol Psychiatr Sci 2022; 31: e9.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.